^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

FLT3‐ITD + WT1 mutation

i
Other names: FLT3, Fms Related Tyrosine Kinase 3, Receptor-Type Tyrosine-Protein Kinase FLT3, Stem Cell Tyrosine Kinase 1, Fms-Like Tyrosine Kinase 3, CD135, FLK-2, STK1, Growth Factor Receptor Tyrosine Kinase Type III, Fetal Liver Kinase 2, WT1, WT1 Transcription Factor, Wilms Tumor Protein, Wilms Tumor 1, WT33, NPHS4, WIT-2, AWT1, WAGR, GUD
Entrez ID:
1year
Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia. (PubMed, Haematologica)
Cooperating FLT3-ITD and WT1 mutations define NUP98-NSD1, and chromosome 13 aberrations are highly enriched in NUP98-KDM5A. Importantly, we demonstrate that NUP98 fusions portend dismal overall survival, with the noteworthy exception of patients bearing abnormal chr13.
Journal
|
FLT3 (Fms-related tyrosine kinase 3) • WT1 (WT1 Transcription Factor) • NUP98 (Nucleoporin 98 And 96 Precursor 2) • NSD1 (Nuclear Receptor Binding SET Domain Protein 1) • KDM5A (Lysine Demethylase 5A)
|
FLT3-ITD mutation • WT1 mutation • FLT3‐ITD + WT1 mutation
over1year
Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome (ASH 2022)
This analysis of a large cohort of adult patients with newly diagnosed AML revealed that UBTFmutations can be found in about 1% of all patients with AML, but are considerably more common in young adults. As in pediatric patients, they are associated with a specific cytogenetic and molecular profile, i.e. high rate of +8, FLT3-ITD and WT1 mutations. As a novel finding, adult UBTF-TD patients frequently showed signs of myelodysplasia.
Clinical
|
FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • WT1 (WT1 Transcription Factor) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • NUP214 (Nucleoporin 214)
|
FLT3-ITD mutation • NPM1 mutation • DNMT3A mutation • CEBPA mutation • WT1 mutation • FLT3‐ITD + WT1 mutation
over1year
UBTF tandem Duplications Account for a Third of Advanced Pediatric MDS without Genetic Predisposition to Myeloid Neoplasia (ASH 2022)
Type of donor, stem cell source and conditioning regimen did not differ between the 2 groups, 74% of pts received a busulfan, cyclophosphamide and melphalan conditioning. UBTF-TDs were detected in 25 of the 104 pts (24%; 16 males/9 females), while 79 pts (76%; 45 males, 34 females) showed no UBTF mutation (UBTF-wt). Variant allelic frequencies of UBTF-TD ranged from 11%-79% (median 41%). Median age at diagnosis in UBTF-TD and UBTF-wt pts was not different (11.0 vs.
Clinical
|
FLT3 (Fms-related tyrosine kinase 3) • RUNX1 (RUNX Family Transcription Factor 1) • WT1 (WT1 Transcription Factor)
|
FLT3-ITD mutation • WT1 mutation • Chr del(7q) • FLT3‐ITD + WT1 mutation
|
cyclophosphamide • melphalan • busulfan
2years
Bedside to Bench and Back: Identifying a New Clinically Relevant Driver in Pediatric Acute Myeloid Leukemia. (PubMed, Blood Cancer Discov)
In this issue of Blood Cancer Discovery, Dr Masayuki Umeda and colleagues identify and comprehensively analyze a novel recurrent UBTF mutation (tandem duplications) in pediatric acute myeloid leukemia. Acute myeloid leukemia cases with UBTF tandem duplications display distinctive biologic features, including association with FLT3-ITD and WT1 mutations and high-risk disease, and appear to represent a new genetic subtype of acute myeloid leukemia.
Journal
|
FLT3 (Fms-related tyrosine kinase 3) • WT1 (WT1 Transcription Factor)
|
FLT3-ITD mutation • WT1 mutation • FLT3‐ITD + WT1 mutation
almost3years
Comparison of high-resolution melting analysis with direct sequencing for detection of FLT3-TKD, FLT3-ITD and WT1 mutations in acute myeloid leukemia. (PubMed, Cancer Treat Res Commun)
Regarded as the desirable characteristic, the present study is generally distinguished by the similar previous ones due to assessing the FFPE BM tissue from the perspective of the type of assessed sample. This discrepancy between our results and those in prior studies may be due to the disparity of the studied population size, adopted methods as well as the sample type. In this survey, regarding to low amount of extracted DNA from the paraffinized samples, the HRM method was efficient in determining the mentioned mutations.
Journal
|
FLT3 (Fms-related tyrosine kinase 3) • WT1 (WT1 Transcription Factor)
|
FLT3-ITD mutation • FLT3 mutation • WT1 mutation • FLT3‐ITD + WT1 mutation
almost3years
Wilms Tumor 1 Mutations Are Independent Poor Prognostic Factors in Pediatric Acute Myeloid Leukemia. (PubMed, Front Oncol)
Multivariate analysis demonstrated that WT1 mutations conferred an independent adverse impact on event-free survival (hazard ratio 1.910, P = 0.001) and overall survival (hazard ratio 1.709, P = 0.020). In conclusion, our findings have demonstrated that WT1 mutations are independent poor prognostic factors in pediatric AML.
Clinical • Journal
|
FLT3 (Fms-related tyrosine kinase 3) • WT1 (WT1 Transcription Factor)
|
FLT3-ITD mutation • WT1 mutation • FLT3-ITD mutation + WT1 mutation • FLT3‐ITD + WT1 mutation